Spero Therapeutics
Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections.
Launch date
Employees
Market cap
CAD101m
Enterprise valuation
CAD21m (Public information from Sep 2024)
Share price
$1.355 SPRO
Cambridge Massachusetts (HQ)
Authorizing premium user...